@article{3121859,
    title = "Cardiogenic shock in cancer",
    author = "Keramida, K. and Parissis, J.T. and Chioncel, O. and Farmakis, D.",
    journal = "Heart Failure Reviews",
    year = "2019",
    volume = "24",
    number = "6",
    pages = "997-1004",
    publisher = "Springer New York LLC",
    issn = "1382-4147",
    doi = "10.1007/s10741-019-09819-9",
    keywords = "bleomycin;  corticosteroid;  endothelin receptor antagonist;  imatinib;  mitoxantrone;  nitric oxide;  platinum derivative;  prostacyclin derivative;  thiotepa;  antineoplastic agent, acute coronary syndrome;  assisted circulation;  cancer survival;  cardiogenic shock;  cardiomyopathy;  chemotherapy;  corticosteroid therapy;  disease association;  early cancer diagnosis;  extracorporeal oxygenation;  heart tamponade;  hiatus hernia;  high risk patient;  human;  lung embolism;  malignant neoplasm;  myocarditis;  overall survival;  patient care;  pericardiocentesis;  pericardiotomy;  prognosis;  pulmonary hypertension;  pulmonary tumor thrombotic microangiopathy;  pulmonary tumor thrombotic microangiopathy;  radiotherapy;  Review;  sclerotherapy;  takotsubo cardiomyopathy;  thromboembolism;  thrombotic thrombocytopenic purpura;  adverse event;  cardiogenic shock;  comparative study;  complication;  mortality;  neoplasm;  procedures;  secondary prevention, Acute Coronary Syndrome;  Antineoplastic Agents;  Cardiac Tamponade;  Cardiomyopathies;  Humans;  Myocarditis;  Neoplasms;  Pulmonary Embolism;  Radiotherapy;  Secondary Prevention;  Shock, Cardiogenic;  Takotsubo Cardiomyopathy",
    abstract = "Cardiogenic shock (CS) is increasingly recognized in patients with malignancies, while cancer is independently associated with worse prognosis in CS. A number of conditions may lead to CS in cancer, including acute coronary syndromes, cardiomyopathy, takotsubo syndrome, myocarditis, pulmonary embolism, tamponade, and cardiac herniation. In these conditions, CS may be related to cancer itself or to cancer therapy, including surgery, chemotherapy, or radiotherapy. Given the significantly improved overall survival of patients with malignancies, the early recognition and proper management of CS in cancer become increasingly important. In the present paper, we review the available evidence on CS in patients with malignancies and highlight issues related to its management. © 2019, Springer Science+Business Media, LLC, part of Springer Nature."
}